Hydroxyurea therapy for sickle cell anemia

Expert Opinion on Drug Safety

Volumn 14, Issue 11, 2015, Pages 1749-1758

  McGann, Patrick T ^a   Ware, Russell E ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

fetal hemoglobin; hemoglobinopathies; hydroxyurea; sickle cell anemia

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; HYDROXYUREA; ANTISICKLING AGENT;

AFRICA SOUTH OF THE SAHARA; ALLERGIC REACTION; ANEMIA; BLOOD SMEAR; BONE MARROW SUPPRESSION; CANCER RISK; CLINICAL FEATURE; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; GASTRITIS; GASTROINTESTINAL SYMPTOM; HAIR THINNING; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERPIGMENTATION; HYPERSPLENISM; IN VIVO STUDY; LEUKOCYTE COUNT; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MEDICATION COMPLIANCE; NAIL HYPERPIGMENTATION; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; PATIENT CARE; RASH; RETICULOCYTE COUNT; RETICULOCYTOPENIA; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; SKIN ULCER; SURVIVAL; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING; ANEMIA, SICKLE CELL; ANIMAL; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANEMIA, SICKLE CELL; ANIMALS; ANTISICKLING AGENTS; HUMANS; HYDROXYUREA;

EID: 84947494332     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1088827     Document Type: Review

References (71)

1. Hassell KL. Population Estimates of Sickle Cell Disease in the U.S. Am J Prev Med 2010;38(4):S512-21
2. Piel FB, Hay SI, Gupta S, et al. Global Burden of Sickle Cell Anaemia in Children under Five, 2010-2050: Modelling Based on Demographics, Excess Mortality, and Interventions. PLoS Med 2013;10(7):e1001484
3. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010;115(17):3447-52
4. Telfer P, Coen P, Chakravorty S, et al. Clinical outcomes in children with sickle cell disease living in England: A neonatal cohort in East London. Haematologica 2007;92(7):905-12
5. McGann PT. Sickle cell anemia: an underappreciated and unaddressed contributor to global childhood mortality. J Pediatr 2014;165(1):18-22
6. Grosse SD, Odame I, Atrash HK, et al. Sickle cell disease in Africa: A neglected cause of early childhood mortality. Am J Prev Med 2011;41(6 Suppl 4):S398-405
7. Letvin NL, Linch DC, Beardsley GP, et al. Augmentation of Fetal-Hemoglobin Production in Anemic Monkeys by Hydroxyurea. N Engl J Med 1984;310(14):869-73
8. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984;74:652-6
9. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79(10):2255-65
10. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members. JAMA 2014;312(10):1033-48
11. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377(9778):1663-72
12. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332(20):1317-22
13. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;289(13):1645-51
14. Kinney TR, Helms RW, O'Branski EE, et al. Safety of Hydroxyurea in Children With Sickle Cell Anemia: Results of the HUG-KIDS Study, a Phase I/II Trial. Blood 1999;94(5):1550-4
15. Hankins JS, Helton KJ, McCarville MB, et al. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer 2008;50(2):293-7
16. Wang WC, Wynn LW, Rogers ZR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 2001;139(6):790-6
17. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103(6):2039-45
18. Estepp JH, Smeltzer MP, Kang G, et al. Higher Fetal Hemoglobin Following Escalation of Hydroxyurea to Maximum Tolerated Dose Provides Clinical Benefit to Children with Sickle Cell Anemia. Blood 2014;124(21); ASH Annual Meeting Abstract
19. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood 2005;106(7):2269-75
20. Lopes de Castro Lobo C, Pinto JFC, Nascimento EM, et al. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol 2013;161(6):852-60
21. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010;115(12):2354-63
22. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010;85(6):403-8
23. Lê Q, Gulbus B, Dedeken L, et al. Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment. Pediatr Blood Cancer 2015; doi: 10.1002/pbc.25608. [Epub ahead of print]
24. Dresler W, Stein R. Ueber den hydroxylharnstoff. Justus Liebigs Annalen der Chemie 1869
25. Rees DC. The rationale for using hydroxycarbamide in the treatment of sickle cell disease. Haematologica 2011;96(4):488-91
26. Cole DR, Beckloff GL, Rousselot LM. Clinical results with hydroxyurea in cancer chemotherapy. NY State J Med 1965;65:2132-6
27. Bloedow CE. Phase II studies of hydroxyurea (NSC-32065) in adults: miscellaneous tumors. Cancer Chemother Rep 1964;40:39-41
28. Dahl M, Comaish JS. Long-term effects of hydroxyurea in psoriasis. BMJ 1972;5840:585-7
29. Kennedy BJ. Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 1972;29(4):1052-6
30. Donovan PB, Kaplan ME, Goldberg JD, et al. Treatment of polycythemia vera with hydroxyurea. Am J Hematol 1984;7(4):329-34
31. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;5186:801-5
32. Ariel IM. Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors. Cancer 1970;25(3):705-14
33. Cassileth PA, Hyman GA. Treatment of malignant melanoma with hydroxyurea. Cancer Res 1967;27(10):1843-5
34. Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess 2008;165:1-95
35. Lebensburger JD, Pestina TI, Ware RE, et al. Hydroxyurea Therapy Requires HbF Induction for Clinical Benefit in a Sickle Cell Mouse Model. Haematalogica 2010;95(9):1599-603
36. Elford HL. Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 1968;33(1):129-35
37. Alvino GM, Collingwood D, Murphy JM, et al. Replication in Hydroxyurea: It's a Matter of Time. Mol Cell Biol 2007;27(18):6396-406
38. Koç A, Wheeler LJ, Mathews CK, Merrill GF. Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools. J Biol Chem 2004;279(1):223-30
39. Baliga BS, Pace BS, Chen HH, et al. Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors. Am J Hematol 2000;65(3):227-33
40. Stamatoyannopoulos G, Veith R, Galanello R, et al. Production in Stressed Erythropoiesis: Observations and Kinetic Models. Ann NY Acad Sci 1985;445:188-97
41. Bridges KR, Barabino GD, Brugnara C, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996;88(12):4701-10
42. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003;111(2):231-9
43. Almeida CB, Scheiermann C, Jang JE, et al. Hydroxyurea and a cGMPamplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood 2012;120(14):2879-88
44. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 2004;145(3):346-52
45. Ware RE, Helms RW; SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood 2012;119(17):3925-32
46. Hankins JS, Aygun B, Nottage K, et al. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Medicine 2014;93(28):e215
47. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010;115(26):5300-11
48. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 2011;118(18):4985-91
49. de Montalembert M, Bachir D, Hulin A, et al. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. Haematologica 2006;91(12):1685-8
50. Rodriguez GI, Kuhn JG, Weiss GR, et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 1998;91(5):1533-41
51. McGann PT, Sparreboom A, Mortier NA, et al. Hydroxyurea Pharmacokinetics for Predicting Maximum Tolerated Dose in Children with Sickle Cell Anemia. Blood 2014;124(21):2707; (ASH Annual Meeting Abstract)
52. Dong M, McGann PT, Mizuno T, et al. A Prediction of Maximum Tolerated Dose (MTD) for Hydroxyurea Treatment using Bayesian Adaptive Control in Children with Sickle Cell Anaemia. 2015 (Manuscript under review)
53. Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 1994;52(3):134-9
54. Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011;29(17):2410-15
55. Schulz WH, Ware RE. Malignancy in patients with sickle cell disease. Am J Hematol 2003;7(4):249-53
56. Agbaraji VO, Scott RB, Leto S. Fertility studies in sickle cell disease: semen analysis in adult male patients. Int J Fertil 1988;33(5):347-52
57. Anele UA, Burnett AL. Erectile Dysfunction after Sickle Cell Disease-Associated Recurrent Ischemic Priapism: Profile and Risk Factors. J Sex Med 2015;12(3):713-19
58. Morrison BF, Anele UA, Reid ME, et al. Is testosterone deficiency a possible risk factor for priapism associated with sicklecell disease? Int Urol Nephrol 2014;47(1):47-52
59. Zemel BS, Kawchak DA, Ohene-Frempong K, et al. Effects of delayed pubertal development, nutritional status, and disease severity on longitudinal patterns of growth failure in children with sickle cell disease. Pediatr Res 2007;61:607-13
60. Abudu EK, Akanmu SA, Soriyan OO, et al. Serum testosterone levels of HbSS (sickle cell disease) male subjects in Lagos. Nigeria. BMC Res Notes 2011;4:298
61. Osegbe DN, Akinyanju O, Amaku EO. Fertility in males with sickle cell disease. Lancet 1981;2(8241):275-6
62. DeBaun MR. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: A review. Expert Rev Hematol 2014;7(6):767-73
63. Jones KM, Niaz MS, Brooks CM, et al. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints. Int J Environ Res Public Helath 2009;6(3):1124-44
64. Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008;93(7):988-93
65. Ballas SK, McCarthy WF, Guo N, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J National Med Assoc 2009;101(10):1046-51
66. Oteng-Ntim E, Meeks D, Seet PT, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood 2015;125(21):3316-25
67. World Health Organization: Regional Office for Africa. Sickle-cell disease: A strategy for the WHO African Region. June 2010
68. WHO Model List of Essential Medicines for Children, 4th List. April 2013, Geneva, Switzerland
69. McGann PT, Tshilolo L, Santos B, et al. Hydroxyurea Therapy for Children with Sickle Cell Anemia: Rationale and Design of the REACH Trial. Pediatr Blood Cancer 2015; in press
70. Stettler N, McKiernan CM, Melin CQ, et al. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. JAMA 2015;313(16):1671-2
71. Gaston M, Rosse W. The cooperative study of sickle cell disease Review of study design and objectives. Am J Pediatr Hematol/Oncol 1982;4(2):197-201